News & Event

GENE-EDITING TREATMENT APPROVED BY HEALTH CANADA FOR SICKLE CELL DISEASE AND THALASSEMIA WAS TESTED IN ST. PAUL’S HOSPITAL CLINICAL TRIAL A gene editing treatment for sickle-cell disease (SCD) and transfusion-dependent beta-thalassemia (TDT) has received marketing authorization from Health Canada, following the results of a first-in-Canada

#SaveTheDate – The 1st TIF Pan American Conference on Thalassaemia & Other Haemoglobin Disorders & the 2nd RAIN Summit are coming to Washington D.C.! 🗓️ 11 – 13 July 2025 📍 Hyatt Regency Crystal City, Washington D.C., US 🗣️ In-person attendance only This landmark event,

Thalassemia is a genetic blood disorder that affects millions worldwide, including in Canada...